KIROMIC BIOPHARMA INC (KRBP)

Company Profile

Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. The company is headquartered in Houston, Texas and currently employs 31 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.

Company Info

KIROMIC BIOPHARMA INC

7707 Fannin St., Suite 140

Houston TEXAS 77054

P: 18329684888.0

CEO: Maurizio Chiriva-Internati

Employees: 31

Website: https://kiromic.com/